학술논문
354TiP A phase III randomised open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy (ET) in patients with ER+/HER2– early breast cancer (BC) and an intermediate or high risk of recurrence (CAMBRIA-1)
Document Type
Abstract
Author
Source
In Annals of Oncology October 2023 34 Supplement 2:S323-S324
Subject
Language
ISSN
0923-7534